Clinical Trials Browser

Burkitt Lymphoma × tafasitamab × Clear all

NCT05453500 2026-05-11

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting

Burkitt Lymphoma

NCT01685021 2018-02-22

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Terminated

22 enrolled 12 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma